Alterations in serotype-specific B cell responses to the 13-valent pneumococcal conjugate vaccine in aging HIV-infected adults |
| |
| Affiliation: | 1. Department of Medicine, University of Toledo College of Medicine & Life Sciences, Toledo, OH, United States;2. Department of Pathology, University of Toledo College of Medicine & Life Sciences, Toledo, OH, United States;3. Department of Medical Microbiology and Immunology, University of Toledo College of Medicine & Life Sciences, Toledo, OH, United States;4. Department of Public Health and Preventative Medicine, University of Toledo College of Medicine & Life Sciences, Toledo, OH, United States;1. Departamento de Zoología y Antropología Física, Universidad Complutense de Madrid, C/ José Antonio Novais, 12, 28040 Madrid, Spain;2. Agencia de Medio Ambiente y Agua, Consejería de Medio Ambiente y Ordenación del Territorio, Junta de Andalucía, C/ Joaquina Eguaras, 10, 18013 Granada, Spain;3. Departamento de Biología y Geología, Escuela Superior de Ciencias Experimentales y Tecnología, Universidad Rey Juan Carlos, C/ Tulipán, s/n, 28933 Móstoles, Madrid, Spain;1. Department of Cardiology, Munich University Clinic, Ludwig-Maximilian University, Munich, Germany;2. Munich Heart Alliance at Deutsches Zentrum für Herz-Kreislauf-Forschung E.V., Munich, Germany |
| |
| Abstract: | BackgroundAdvanced age and human immunodeficiency virus (HIV) infection are associated with increased pneumococcal disease risk. The impact of these factors on cellular responses to vaccination is unknown.MethodsHIV-infected (HIV+) individuals 50–65 years old with CD4+ T cells/μl (CD4) >200 on antiretroviral therapy (ART) ≥1 year received either the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine (PCV/PPV) or PPV only. HIV-uninfected (HIV−) controls received PCV/PPV. Phenotype distribution and surface expression of complement receptor CD21 and tumor necrosis factor superfamily receptors (TNFRs) were compared on serotype-specific B cells postvaccination.ResultsPostvaccination serotype-specific B cell percentages were significantly lower in HIV+ PCV/PPV compared to PPV groups, but similar between HIV+ or HIV− PCV/PPV groups. Transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI)+ serotype-specific B cell percentages were significantly decreased in HIV+ PCV/PPV compared to PPV groups. CD21+ serotype-specific B cells were significantly higher in HIV− compared to HIV+ PCV/PPV groups.ConclusionsAn initial dose of PCV reduced the frequency, but not phenotype distribution, of serotype-specific B cells and also lowered TACI expression in aging HIV+ subjects postvaccination with PPV. These findings suggest that PCV does not enhance cellular responses to revaccination with PPV. |
| |
| Keywords: | HIV infection Aging B cells Pneumococcal conjugate vaccine Pneumococcal polysaccharide vaccine |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
